Preparation and First Preclinical Evaluation of [(18)F]FE@SNAP: A Potential PET Tracer for the Melanin-Concentrating Hormone Receptor-1 (MCHR1)

Overview

Journal Sci Pharm

Publisher MDPI

Specialty Pharmacology

Date 2013 Oct 10

PMID 24106662

Citations 7

Authors

Cecile Philippe

Lukas Nics

Markus Zeilinger

Eva Schirmer

Helmut Spreitzer

Georgios Karanikas

Rupert Lanzenberger

Helmut Viernstein

Wolfgang Wadsak

Markus Mitterhauser

Affiliations

Soon will be listed here.

Abstract

The melanin-concentrating hormone (MCH) system is a new target for the treatment of human disorders. Since the knowledge of the MCH system's involvement in a variety of pathologies (obesity, diabetes, and deregulation of metabolic feedback mechanism) is based on in vitro or preclinical studies, a suitable positron emission tomography (PET) tracer needs to be developed. We herein present the preparation and first preclinical evaluation of [(18)F]FE@SNAP - a new PET tracer for MCH receptor-1 (MCHR1). The synthesis was performed using a microfluidic device. Preclinical evaluation included binding affinity, plasma stability, plasma free fraction, stability against the cytochrome P-450 (CYP450) system using liver microsomes, stability against carboxyl-esterase, and methods to assess the penetration of the blood-brain barrier (BBB) such as logD analysis and immobilized artificial membrane (IAM) chromatography. Levels at 374 ± 202 MBq [(18)F]FE@SNAP were obtained after purification. The obtained K d value of [(18)F]FE@SNAP was 2.9 nM. [(18)F]FE@SNAP evinced high stability against carboxylesterase, CYP450 enzymes, and in human plasma. LogD (3.83) and IAM chromatography results (Pm=0.51) were in the same range as for known BBB-penetrating compounds. The synthesis of [(18)F]FE@SNAP was reliable and successful. Due to high binding affinity and stability, [(18)F]FE@SNAP is a promising tracer for MCHR1.

Citing Articles

The historical progression of positron emission tomography research in neuroendocrinology.

Bini J Front Neuroendocrinol. 2023; 70:101081.

PMID: 37423505 PMC: 10530506. DOI: 10.1016/j.yfrne.2023.101081.

Discovery of melanin-concentrating hormone receptor 1 in brown adipose tissue.

Philippe C, Klebermass E, Balber T, Kulterer O, Zeilinger M, Egger G Ann N Y Acad Sci. 2021; 1494(1):70-86.

PMID: 33502798 PMC: 8248337. DOI: 10.1111/nyas.14563.

Rapidly (and Successfully) Translating Novel Brain Radiotracers From Animal Research Into Clinical Use.

Shaw R, Tamagnan G, Tavares A Front Neurosci. 2020; 14:871.

PMID: 33117115 PMC: 7559529. DOI: 10.3389/fnins.2020.00871.

Radiopharmaceutical Evidence for MCHR1 Binding Sites in Murine Brown Adipocytes.

Balber T, Bencurova K, Kiefer F, Kulterer O, Klebermass E, Egger G Front Endocrinol (Lausanne). 2019; 10:324.

PMID: 31244769 PMC: 6581027. DOI: 10.3389/fendo.2019.00324.

SNAPshots of the MCHR1: a Comparison Between the PET-Tracers [F]FE@SNAP and [C]SNAP-7941.

Philippe C, Zeilinger M, Dumanic M, Pichler F, Fetty L, Vraka C Mol Imaging Biol. 2018; 21(2):257-268.

PMID: 29948643 PMC: 6449294. DOI: 10.1007/s11307-018-1212-0.

References

Luthin D . Anti-obesity effects of small molecule melanin-concentrating hormone receptor 1 (MCHR1) antagonists. Life Sci. 2007; 81(6):423-40. DOI: 10.1016/j.lfs.2007.05.029. View

Philippe C, Ungersboeck J, Schirmer E, Zdravkovic M, Nics L, Zeilinger M . [¹⁸F]FE@SNAP-A new PET tracer for the melanin concentrating hormone receptor 1 (MCHR1): microfluidic and vessel-based approaches. Bioorg Med Chem. 2012; 20(19):5936-40. PMC: 3460236. DOI: 10.1016/j.bmc.2012.07.051. View

Mashiko S, Ishihara A, Gomori A, Moriya R, Ito M, Iwaasa H . Antiobesity effect of a melanin-concentrating hormone 1 receptor antagonist in diet-induced obese mice. Endocrinology. 2005; 146(7):3080-6. DOI: 10.1210/en.2004-1150. View

Tavares A, Lewsey J, Dewar D, Pimlott S . Radiotracer properties determined by high performance liquid chromatography: a potential tool for brain radiotracer discovery. Nucl Med Biol. 2011; 39(1):127-35. DOI: 10.1016/j.nucmedbio.2011.06.011. View

Philippe C, Nics L, Zeilinger M, Kuntner C, Wanek T, Mairinger S . Preclinical in vitro &in vivo evaluation of [(11)C]SNAP-7941 - the first PET tracer for the melanin concentrating hormone receptor 1. Nucl Med Biol. 2013; 40(7):919-25. DOI: 10.1016/j.nucmedbio.2013.05.010. View

Lembo P, Grazzini E, Cao J, Hubatsch D, Pelletier M, Hoffert C . The receptor for the orexigenic peptide melanin-concentrating hormone is a G-protein-coupled receptor. Nat Cell Biol. 1999; 1(5):267-71. DOI: 10.1038/12978. View

Philippe C, Schirmer E, Mitterhauser M, Shanab K, Lanzenberger R, Karanikas G . Radiosynthesis of [11C]SNAP-7941--the first PET-tracer for the melanin concentrating hormone receptor 1 (MCHR1). Appl Radiat Isot. 2012; 70(10):2287-94. PMC: 3439630. DOI: 10.1016/j.apradiso.2012.07.010. View

Tadayyon M, Welters H, Haynes A, Cluderay J, Hervieu G . Expression of melanin-concentrating hormone receptors in insulin-producing cells: MCH stimulates insulin release in RINm5F and CRI-G1 cell-lines. Biochem Biophys Res Commun. 2000; 275(2):709-12. DOI: 10.1006/bbrc.2000.3357. View

Casatti C, Elias C, Sita L, Frigo L, Furlani V, Bauer J . Distribution of melanin-concentrating hormone neurons projecting to the medial mammillary nucleus. Neuroscience. 2002; 115(3):899-915. DOI: 10.1016/s0306-4522(02)00508-0. View

10.

Bradley R, Mansfield J, Maratos-Flier E, Cheatham B . Melanin-concentrating hormone activates signaling pathways in 3T3-L1 adipocytes. Am J Physiol Endocrinol Metab. 2002; 283(3):E584-92. DOI: 10.1152/ajpendo.00161.2002. View

11.

Borowsky B, Durkin M, Ogozalek K, Marzabadi M, DeLeon J, Lagu B . Antidepressant, anxiolytic and anorectic effects of a melanin-concentrating hormone-1 receptor antagonist. Nat Med. 2002; 8(8):825-30. DOI: 10.1038/nm741. View

12.

Gattrell W, Sambrook Smith C, Smith A . An example of designed multiple ligands spanning protein classes: dual MCH-1R antagonists/DPPIV inhibitors. Bioorg Med Chem Lett. 2012; 22(7):2464-9. DOI: 10.1016/j.bmcl.2012.02.010. View

13.

An S, Cutler G, Zhao J, Huang S, Tian H, Li W . Identification and characterization of a melanin-concentrating hormone receptor. Proc Natl Acad Sci U S A. 2001; 98(13):7576-81. PMC: 34710. DOI: 10.1073/pnas.131200698. View

14.

Ungersboeck J, Philippe C, Mien L, Haeusler D, Shanab K, Lanzenberger R . Microfluidic preparation of [18F]FE@SUPPY and [18F]FE@SUPPY:2--comparison with conventional radiosyntheses. Nucl Med Biol. 2011; 38(3):427-34. DOI: 10.1016/j.nucmedbio.2010.09.009. View

15.

Shimomura Y, Mori M, Sugo T, Ishibashi Y, Abe M, Kurokawa T . Isolation and identification of melanin-concentrating hormone as the endogenous ligand of the SLC-1 receptor. Biochem Biophys Res Commun. 1999; 261(3):622-6. DOI: 10.1006/bbrc.1999.1104. View

16.

Nics L, Haeusler D, Wadsak W, Wagner K, Dudczak R, Kletter K . The stability of methyl-, ethyl- and fluoroethylesters against carboxylesterases in vitro: there is no difference. Nucl Med Biol. 2011; 38(1):13-7. DOI: 10.1016/j.nucmedbio.2010.07.004. View

17.

Chambers J, Ames R, BERGSMA D, Muir A, FITZGERALD L, Hervieu G . Melanin-concentrating hormone is the cognate ligand for the orphan G-protein-coupled receptor SLC-1. Nature. 1999; 400(6741):261-5. DOI: 10.1038/22313. View

18.

Wang S, Behan J, ONeill K, Weig B, Fried S, Laz T . Identification and pharmacological characterization of a novel human melanin-concentrating hormone receptor, mch-r2. J Biol Chem. 2001; 276(37):34664-70. DOI: 10.1074/jbc.M102601200. View

19.

Parsey R, Slifstein M, Hwang D, Abi-Dargham A, Simpson N, Mawlawi O . Validation and reproducibility of measurement of 5-HT1A receptor parameters with [carbonyl-11C]WAY-100635 in humans: comparison of arterial and reference tisssue input functions. J Cereb Blood Flow Metab. 2000; 20(7):1111-33. DOI: 10.1097/00004647-200007000-00011. View

20.

Ito M, Gomori A, Ishihara A, Oda Z, Mashiko S, Matsushita H . Characterization of MCH-mediated obesity in mice. Am J Physiol Endocrinol Metab. 2003; 284(5):E940-5. DOI: 10.1152/ajpendo.00529.2002. View